Physician profile
Destiny Mathis
NPI 1609452630
$1,271.82
in general payments reported to CMS, 2019-2025
11 companies · $469 in 2025
The $469 reported for 2025 was more than what 88% of Registered Nurse providers received nationally (typical 2025 total: $73.55).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $23.90 · 2023: $232 · 2024: $547 · 2025: $469.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,248.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,247.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $709.54 | 2023-2025 | |
| Astrazeneca Pharmaceuticals Lp | $207.93 | 2024-2025 | Airsupra |
| Novo Nordisk INC | $100.88 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| Glaxosmithkline, LLC. | $83.87 | 2024-2025 | Trelegy Ellipta |
| Exact Sciences Corporation | $50.19 | 2023-2024 | Cologuard Collection Kit |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $24.67 | 2025 | Caplyta |
| Medtronic, INC. | $23.90 | 2022 | |
| Pharmacosmos Therapeutics INC. | $21.80 | 2023 | Monoferric |
| Amgen INC. | $18.21 | 2025 | Krystexxa |
| Lilly USA, LLC | $16.27 | 2024 | Mounjaro |
| Pfizer INC. | $14.56 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Destiny Mathis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.